Economic impact of tobramycin in patients with cystic fibrosis in a managed care population

Journal of Medical Economics

Volumn 14, Issue 6, 2011, Pages 759-768

  Wertz, Debra A ^a   Chang, Chun Lan ^a   Stephenson, Judith J ^a   Zhang, Jie ^b   Kuhn, Robert J ^c  

^a HEALTHCORE INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cost; Cystic fibrosis; Expenditures; Outcomes; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLISTIN; CORTICOSTEROID; DORNASE ALFA; LEUKOTRIENE; LONG ACTING BETA AGONIST; SHORT ACTING BETA AGONIST; SODIUM CHLORIDE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TOBRAMYCIN; YOUNG ADULT;

EID: 81255165701     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.621004     Document Type: Article

References (28)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2007 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2007
2. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic edications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69 (Pubitemid 350127838)
3. TOBI- (tobramycin inhalation solution) [package insert]. East Hanover, NJ: Novrtis Pharmaceuticals Corporation, 2008
4. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340: 23-30 (Pubitemid 29024680)
5. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-6 (Pubitemid 29196500)
6. MacLuskey IB, Gold R, Corey M, et al. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-8
7. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6 (Pubitemid 23170123)
8. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care 2003; 168:918-51 (Pubitemid 37267172)
9. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100 (Pubitemid 34809519)
10. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138:699-704 (Pubitemid 32417671)
11. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-9
12. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52 (Pubitemid 32144560)
13. Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994;49:115-20
14. Sacket DL, Snow JC. The magnitude of compliance and non-compliance. In: Hayes RB, Taylor WB, Sacket DL, eds. Compliance in healthcare. Baltimore, MD: John Hopkins University Press, 1977. p 11-22
15. Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33 (Pubitemid 26047099)
16. Briesacher BA, Quittner A, Saiman L, et al. Adherence to tobramycin inhaled solution and health care utilization [abstract]. Am J Respir Crit Care Med 2009;179:A1183
17. Van Devanter DR, O'Riordan MA, Blumer JL, et al. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010;11:137
18. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
19. Blumer JL, Saiman L, Konstan MW, et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128:2336-46 (Pubitemid 41507577)
20. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial. Thorax 2010;65:286-91
21. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009; 30:256-68
22. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, doubleblind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92 (Pubitemid 28110583)
23. O'Sullivan A, Sullivan JK, Higuchi K. Medication compliance and impact on health-care resource utilization and mortality among cystic fibrosis patients with P aeruginosa. [abstract] Pediatr Pulmonol 2008;43(S31):A584
24. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96
25. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72
26. Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2:84-90 (Pubitemid 36814095)
27. O'Sullivan AK, Sullivan JM, Higuchi K. Health-care utilization and costs evaluation of pediatric and adult patients with cystic fibrosis treated for pulmonary manifestations. [abstract] Pediatr Pulmonol 2008;43(S31):A583
28. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine 2011;11:5, doi:10.1186/1471-2466-11-5